DNA double-strand break repair, chromosomes translocations and cancer

描述（由申请人提供）：DNA双链断裂（DSB）修复可防止持续DNA损伤，抵消基因组不稳定性并抑制肿瘤发展。然而，DSB修复也有可能产生致癌染色体易位和重排。这个高度整合的项目将阐明DSB修复启动的机制和调控，以及它对淋巴瘤和乳腺癌模型DSB修复选择、染色体易位和癌症发展的影响。特别是，该计划将研究微同源介导的末端连接（MMEJ）的调控，这是DSB修复的一种致病形式，负责很大一部分致瘤性染色体易位。所有项目的初步研究都集中在DNA加工和CtIP上，形成了一个集中而有凝聚力的项目。Symington博士将使用遗传分析来评估DNA切除如何影响MMEJ，并调查MMEJ与其他DSB修复模式之间的竞争。赛明顿博士还将开发灵敏的哺乳动物细胞物理切除试验，这是目前明显缺乏的技术。Drs。Gautier和Gottesman将研究在dsb（一种参与MMEJ的中间体）上产生持久的短ssDNA悬垂的机制。他们的研究将集中在CtIP的作用上，CtIP是一种参与DNA切除起始的蛋白质。在第三个项目中。Zha和Dalla-Favera将评估这个角色

DESCRIPTION (provided by applicant): DNA double-strand break (DSB) repair prevents persistent DNA damage, counteracts genome instability and suppresses tumor development. However, DSB repair also has the potential to produce oncogenic chromosome translocations and rearrangements. This highly integrated program will elucidate the mechanism and regulation of DSB repair initiation and its impact on DSB repair choice, chromosome translocation and cancer development in model of lymphoma and breast cancer. In particular, the program will investigate the regulation of microhomology-mediated end-joining (MMEJ), a pathogenic form of DSB repair responsible for a significant fraction of tumorigenic chromosome translocations. Preliminary studies from all projects focusing on DNA processing and CtIP have generated a focused and cohesive program. Dr. Symington will use genetic analysis to assess how DNA resection affects MMEJ and to investigate the competition between MMEJ and other modes of DSB repair. Dr. Symington will also develop sensitive physical resection assays in mammalian cells, a technology which is notably lacking at present. Drs. Gautier and Gottesman will study the mechanism(s) that generate persistent, short ssDNA overhangs at DSBs, an intermediate involved in MMEJ. Their studies will focus on the role of CtIP, a protein involved in initiation of DNA resection. In the third project, Drs. Zha and Dalla-Favera will evaluate the role of CtIP in repair of programmed DSBs during lymphocyte development and malignancy. They will also test the hypothesis that CtIP mediates, at least in part, the oncogenic function of c-Myc including its undefined role in genomic instability. Dr. Baer, will determine how CtIP facilitates breast tumor development in p53-deficient mice and will test whether CtIP loss can also suppress basal-like breast cancer in BRCA1-deficient mice. Finally, he will evaluate the potential role of CtIP in Myc-driven breast tumor development. To accomplish these goals, the projects will rely extensively on three interlinked cores: administrative, molecular analysis of genomic instability and pathology. The project and core leaders have a very strong history of collaboration, joint efforts in training and common interests in genome stability and the mechanisms of its loss in cancer.